you use the phrase immediate cease-fire -- [indiscernible] a diplomatic decision-making progress or did to want to apply pressure -- [indiscernible] i don't know. i would not read too much into that. when i say cease-fire, i mean yesterday. the cease-fire is well overdue, the suffering, the number of lives lost, it is too much, but a cease-fire has to be on both sides, hamas as well as israel. thank you. reporter:scerble] >> back, please, behind the rope. [captions copyright national cable sateite corp. 2024] [captioning performed by the national captioning stitute, which is responsible for itscucy visit ncicap.org] >> thank you. >> of course. >> it makes my life easier. thank you.

>> today, house speaker mike johnson hose president biden in in the for the annual friends of ireland luncheon ahead of st. patrick's day on sunday. live coverage begins at 1:30 p.m. on c-span, c-span now, or online at c-span.org. >> biden administration officials, lawmakers and advocates discuss health policy ington dc. during this session, health care and technology. we will watch this as we wait to begin on capitol hill.

stephen:. hello. i am stephen overly. i'm joined by andrew, an oncologist who spent the last decade at the intersection of health care and technology and has had roles at the gates foundation and today is the chief scientific and medical officer at a life sciences companies t andrew, thank you fg us. andrew: thank you. great to be here. stephen: i'm interested in having a conversation about how ai is transforming health care and the need to regulate because it seems that there is a lot of excitement and talk aboutsome oe

but also some fuel frankly a bit like height. so let's start. the company is a precision health company which understands it is care tailored to a patient in their individual oedipal history, environment, and needs, what is the most significant way you are seeing the way ai is transferring the way patients are looked at right now? andrew: even though there is hype and that is true since chatgpast fall. the fact is we have been working on ai and medical care for decades and that originally was in the for of less help a daughter make a better decision, systems in the 1970's. it did notll because the totality of the data and the ability to take what we understand as physicians and interacting with doctors was not there.q> later we move towards augmenting

our ability to diagnose, so looking at cells under slides for pathology, looking at radiology and images from ct or chest x-rays. those technologies have been ay impacting care, but i think where the hype comes in comes into can we get yo those technical things that are behind the experience of the patient and push into what does that patient see, so how can they access information generated by him or about them in a different way. pres. biden: care behind the scenes before the patient is necessarily involved in what they actually interact with. steven: when i talk to folks about ai and health of the regular topics they bring up his drug development and the potential for ai to speed up breakthroughs in medical discoveries. i guess one question i have is

to what extent is that real today versus something that we are looking to or in the future that there is this potential for an innovation utopia were medical breakthroughs, clinical trials, all of that happens at a faster pace? andrew: this is an area of intense interest uncertainly has been accelerating over the last couple of years. so there has been a lot of excitement in our companies here at alphabet, particular from deep mind, one groups that got pulled into alphabet as an acquisition and has spun out something called isomorphic, using ai protein structures, something that has eluded scientists for a long time so now a computer can do that and the q■&■nst these pe figure out where to drop them, so if there might be a target, we can build the drug more easily. they are just one example of companies that do the same

thing. that does not mean it is a medicine though. steven: right. andrew: that is the part that has been harder. even companies doing this for a long time haven't yet gotten to a regulatory filing and of medicine available on the market, so we are still waiting to see cannabis still speed things up, but it is promising. steven: is that the big hurdle still to be achieved, taking this and making real drugs that help people? andrew: absolutely. the science is there. s not mean that is tolerable or safe, so going through what is now the pathway that fda have laid out and otheí regulators worldwide to show that drugs or the potential medicine is safe and effective. i think those are key steps tha speaking of --steven: speaking of the fda, i want to talk about the regular tory aspects of ai which is only as good as the data driving it.

you have to acquire a lot of data and in the case of health care a lot of personal de■hata and companies like verily are being entrusted with the information, some protected by hepa and other privacy regulation, but some not, so i'm wondering what regulation might be missing that is needed as ai comes the norm? andrew: it is a great question. certainly after the biden white house but for the executive order on ai the subtext of that was showing ai touches every aspect of life and there is the potential for us as a society to recognize where is the most sensitive data about an individual and how can we protected, but not as huaps alle these tools and have better diagnosis, faster care, cheaper care. that is the promise that we believe ai can get us to.

steven: the vision we are working towards. andrew: right, but to get there we have to understand where people feel comfortable today and understanding what data could they contribute, what data can they■ generate, and what is done already within th health systemre and what they can do to have control over the data. that is not enshrined in data like hepa even though it did not anticipate the data revolution but i think there are opportunities to update demonstrate what is good for the society and how we still protect individual rights around control particularly what data and what its used for. steven: how much of the responsibility is to come up with those rules like a company that discloses how the data used in that sort of thing? andrew: everybody would like to see regulations are clear. we want to take steps --

sensitive data about a person so disclose a consent with the process of informing a person this is how the data can be used and how we will not use it. we will never sell it as a■on example. those are reasonable guidelines all companies that work and health care should follow but that has to be enshrined in regulation. steven: continuing with regulation, washington is in the early stages of figuring out whatneed to be set around ai. there is this coalition of health ai industry andcathese se health care space. google, your parent company, is part of the coalition, so one question i'le what is the appropriate role for private sector companies that have a financial interest at play standards that will govern our health care data? andrew: i think the coalition

for health ai is a great example where private together to recognize the needs for patient advocacy for providers and government officials. there are multiple stakeholderse regulation, and the goal, we will see how it comes about, but the goal is to allow each stakeholder to have a voice and to impact how these regulations can come about, but these t step where we don't have to rely upon fda or other government agencies to keep up with all of the changes that are happening. ai is moving at such a clip at the moment it would be really hard to imagine anyone even those people working on it being able to keep ahead, so instead the assurance labs can be one of those areas,at technologies cane about. steven: when you talk to tech

folks about innovation there is a sponsor of move fast and break the things. when i talked to doctors, there about the data, thehh study, wht we are talking about at the conference, two different cases of innovation, and as someone who lives between those two worlds, how do you reconcile that and do fall into one camp or the other? andrew: there is a huge tension in my brain because of that. i fall more on the idea of showing data but recognize adoption within the health system today is glacial. and for some innovations it has been almost generational. you have to wait for the new doctorsart using it and that is not appropriate. there are people who today we can affect their lives and they can live betr, longer, healthier lives with technologies that exist today.

just the gatekeeping elements of how the health system is set q,up reduces the applicability s that there is an equitable question about how people access these tools, and sometimes that is the health system itself, the actors within it, the physicians , payers, so that could be regulated as well. steven: that is an interesting point because ai for however powerful it is and whatever breakthroughs it delivers will be integrated into an existing system that wew be improved certainly. i want to ask about a couple of those. one is the cause question because when you talk to people abt care, calls concerns is one of the first things they talk about. is ai going to make health care cheaper? more expensive? ■x will it ultimately be something that really benefits the wealthy? andrew: i think tha a reasonable concern and absolutely something we have to recognize,